Claims
- 1. A compound according to formula I
- 2. A compound according to claim 1 wherein:
R1 is alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5;
alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; aryl of 6 to 10 carbon atoms, optionally substituted with one to two groups selected independently from R5; cycloaliyl of 3 to 8 carbon atoms, optionally substituted with one to two groups selected independently from R5; saturated or unsaturated mono or bicyclic heterocycle of from 5 to 10 members containing one heteroatom selected from O, S or NR7, optionally substituted with one to two groups selected independently from R5; or heteroaryl-(CH2)0-6— wherein the heteroaryl group is 5 to 6 membered with one or two heteroatoms selected independently from O, S, and N and may be optionally substituted with one or two groups selected independently from R5; A is —S—, —SO— or SO2—; R2 and R3, taken with the carbon atom to which they are attached, form a 5 to 7 membered heterocyclic ring containing O, S or N—R7 pptionally having one or two double bonds; R4 is hydrogen, alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R5;
alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; phenyl or naphthyl optionally substituted with one or two groups selected independently from R5; C3 to C8 cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected independently from R5; R5 is H, F, Cl, Br, I, CN, CHO, C7-C1, aroyl, C2-C6 alkanoyl, Cl to C12 alkyl, C2 to C12 alkenyl, C2-C12 alkynyl, C1-C6 alkoxy, aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, C1-C6 alkoxyaryl, C1-C6 alkoxyheteroaryl, C1-C6-alkylaMinrC1 C6 alkoxy, C1-C2-alkylene dioxy, aryloxy-C1-C6 alkyl amine, C1-C12 perfluoro alkyL S(0)n-C1-C6 alkyl, S(0)n-aryl where n is 0, 1 or 2; OCOO—C1-C6 alkyl, OCOOaryl, OCONR6, COOH, COO—C1-C6 alkyl, COOaryl, CONR6R6, CONHOH, NR6R6, SO2NR6R6, NR6SO2aryl, NR6CONR6R6, NHSO2CF3, SO2NHheteroaryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, NH2, OH, aryl, heteroaryl, C3 to Cg cycloalkyl; or saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7;
wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected independently from halogen, cyano, aniino, nitro, C1-C6 alkyl, Clc6 alkoxy, or hydroxy; R6 is H, C, to C18 alkyl optionally substituted with OH; C3 to C6 alkenyl, C3 to C6 alkynyl, C, to C6 perfluoro alkyl, S(0)r alkyl or aryl where n is 0, 1, or 2; or COheteroaiyl;
wherein heteroaryl is a 5-10 membered mono orbicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; and R7 is C7-CII aroyl, C2-C6 alkanoyl, C1-C12 perfluoro alkyl, S(0),-alkyl, S(0)n-aryl where n is 0, 1 or 2; COOalkyl, COaryl, CONHR6, CONR6R6, CONHOH, SO2NR6R6,SO2CF3, SO2NHheteroaryl, SO2NHCOaryl,
CONHSO2alkyl, CONHSO2aryl, aryl, heteroaryl; wherein C1-C6 alkyl is straight or branched, heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having from 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having from 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; arylalkyl of 7 to 16 carbon atoms, wherein aryl is optionally substituted with one or two groups selected independently from R5; heteroarylalkl wherein alkyl is from 1 to 6 carbon atoms and heteroaryl contains 1 or 2 heteroatoms selected from O, S or N and is optionally substituted with one or two groups selected independently from R5; biphenylalkyl of 13 to 18 carbon atoms, wherein biphenyl is optionally substituted with one or two groups selected independently from R5; arylalkenyl of 8 to 16 carbon atoms, wherein aryl is optionally substituted with one or two groups selected independently from R5; cycloallylalkyl or bicycloalkylalkyl of 4 to 12 carbon atoms, wherein cycloalkyl or bicycloalkyl is optionally substituted with one or two groups selected independently from R5; saturated or unsaturated mono or bicyclic heterocycle containing one heteroatom selected from O, S or N—C1-C6 alkyl, optionally substituted with one or two groups selected independently from R5; R8R9N—C1-C6-alkoxyaryl-C1-C6-alkyl where R8 and R9r are independently selected from C1-C6 alkyl or R8 and R9 together with the interposed nitrogen forms a 5-7 membered saturated heterocyclic ring optionally containing an oxygen atom, wherein the aryl group is phenyl or naphthyl; or a pharmaceutically acceptable salt thereof.
- 3. A compound according to claim 2 wherein
R1 is phenyl, naphthyl, alkyl of 1-18 carbon atoms or heteroaryl such as pyridyl, thienyl, imidazolyl or faranyl, optionally substituted with C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, halogen; or S(O)n—Cl6alkyl C1-C6 alkoxyaryl or C1-C6 alkoxyheteroaryl; A is —S—, O- or —SO2—; R2 and R3, taken with the carbon atom to which they are attached, form a 5 to 7 membered heterocyclic ring containing O, S or N—R7 optionally having one or two double bonds; R4 is hydrogen,
alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; phenyl or naphthyl optionally substituted with one or two groups selected independently from R5; C3 to C8 cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected independently from R5; R5 is H, C7-Cl, aroyl, C2-C6 alkanoyl, Cl to C12 alkyl,C2 t6 C12 alkenyl, C2-C12 alkynyl, F, Cl, Br, I, CN, CHO, C1-C6 alkoxy, aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, C1-C6 alkylamino-C1-C6 alkoxy, C1-C2 alkylene dioxy, aryloxy-C1-C6 alkyl amine, C1-C12 perfluorQ alkyl, S,(O) i-C1-C6 alkyl, S(0)n-2.5 aryl where n is 0, 1 or 2; OCOO C1-C6 alkyl, OCO0aryl, OCONR6, COOH, COO C1-C6 alkyl, COOaryl, CONR6R6, CONHOH, NR6R6, SO2NR6R6, NR6SO2aryl, —NR6CONR6R6, NHSO2CF3, SO2NHheteroaryl,SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, NH2, OH, aryl, heteroaryl, C3 to C8 cycloalkyl; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S
or NR7, wherein C16 alkyl is straight or branched, heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C16 alkyl, C1-C6 alkoxy, or hydroxy; R6 is H, Cl to C18 alkyl optionally substituted with OH; C3 to C6 alkenyl, C3 to C alkynyl, Cl to C6 perfluoro alky, S(0), alkyl or aryl where n is 0, 1 or 2; or
COheteroaryl; wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alky, C1-C6 alkoxy, or hydroxy; and R7 is CCl, aroyl, C2-C6 alkanoyl, C1-Cl2 perfluoro alkyl, S(0),-alkyl, S(0)n-aryl where n is 0, 1 or 2; COOalkyl, COaryl, CONHR6, CONR6R6, CONHOH, SO2NR6R6,SO2CF3, SO2NHheteroaryl, SO2NHCOaryl, CONHSO2alkyl, CONHSO2aryl, aryl, or heteroaryl; where aryl is phenyl or naphthyl,
optionally substituted by 1 or 2 groups selected independently from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; and heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having, 1 to 3 heteroatoms selected independently from O, S or N—C1-C6 alkyl; alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having from 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having from 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; arylalkyl of 7 to 16 carbon atoms, optionally substituted with one or two groups selected independently from R5; heteroarylalkyl wherein alkyl is from 1 to 6 carbon atoms and heteroaryl contains 1 or 2 heteroatoms selected from O, S or N and is optionally substituted with one or two groups selected independently from R5; biphenylalkyl of 13 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5; arylalkenyl of 8 to 16 carbon atoms, optionally substituted with one or two groups selected independently from R5; cycloalkylalkyl or bicycloalkylalkyl of 4 to 12 carbon atoms, optionally substituted with one or two groups selected independently from R5; saturated or unsaturated mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR—C1-C6 alkyl, optionally substituted with one or two groups selected independently from R5; R8R9N—C1-C6-alkoxyaryl-C1-C6-alkyl where R8 and R9 are independently selected from C1-C6 alkyl or R8 and R9 together with the interposed nitrogen forms a 5-7 membered saturated heterocyclic ring optionally containg an oxygen atom, wherein the aryl group is phenyl or naphthyl; or a pharmaceutically acceptable salt thereof.
- 4. A compound according to claim 1 which is 1-benzyl(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutically acceptable salt thereof.
- 5. A compound according to claim 1 which is 4-(4-methoxy-benzenesulfonyl)-1-(3-methoxy-benzyl)-piperidine-4arboxylic acid hydroxyamide or a pharmaceutically acceptable salt thereof.
- 6. A compound according to claim 1 which is 1-(3,Sdichlorobenzyl) 4-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxamide or a pharmaceutically acceptable salt thereof.
- 7. A compound according to claim 1 which is 4-(4-methoxy-benzenesulfonyl)-1-(4 methylbenzyl)-piperidine-4-carboxylic acid hydroxamide or a pharmaceutically acceptable salt thereof.
- 8. A compound according to claim 1 which is 4-(4-methoxy-benzene-sulfonyl)-1-napthalene-2-yl-methylpiperidine-4-carboxylic acid hydroxamide or a pharmaceutically acceptable salt thereof.
- 9. A compound according to claim 1 which is l-biphenyl1Ayhnethyl,(4-methoxy-benzenesulfonyl)piperidine~carboxylic acid hydroxamide or a pharmaceutically acceptable salt thereof.
- 10. A compound according to claim 1 which is 4-(4-methoxy-benzene-sulfonyl)-1-(3-methyl-but-2-enyl)piperidine~carboxylic acid hydroxamide or a pharmaceutically acceptable salt thereof.
- 11. A compound according to claim 1 which is 1-(4bromo-benzyl)4(methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutically acceptable salt thereof.
- 12. A compound according to claim 1 which is 4-(4-methoxy-benzenesulfonyl)-1-[4-(2 piperidin-1-yl-ethoxy)-benzyl]-piperidine-4-carboxylic acid hydroxy amide or a pharmaceutically accepted salt thereof.
- 13. A compound according to claim 1 which is 1-benzyl4-(4-benzyloxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamde or a pharmaceutical salt thereof.
- 14. A compound according to claim 1 which is 4-(4butoxy-benzenesulfonyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 15. A compound according to claim 1 which is 4-(4butoxy-benzenesulfonyl)-1-[3-(2-morpholnyl-1-ylethoxy)-benzyl]-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 16. A compound according to claim 1 which is 1-methyl-4-(4-butoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 17. A compound according to claim 1 which is 1-ethyl-4-(4-butoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 18. A compound according to claim 1 which is 1-n-butyl(4-butoxy-benzenesulfonyl)-piperidine carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 19. A compound according to claim 1 which is 4-[(4chloro-phenoxy)-benzenesulfonyl]1-methyl-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof
- 20. A compound according to claim 1 which is 4-[4-(4-chloro-phenoxy)-berizenesulfonyl]1-ethyl-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 21. A compound according to claim 1 which is 1-butyl-4-(4-(4-chloro-phenoxy)-benzenesulfonyl]-piperidine~carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 22. A compound according to claim 1 which is l-benzylX[4-(4-chloro-phenoxy)-benzenesulfonyl]-piperidinefcarboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 23. A compound according to claim 1 which is 1-benzyl4[s(3-methyl-butoxy)-benzenesulfonyl]-piperidine-4-carboxylic acid hydroxyamide or apharmaceutical salt thereof.
- 24. A compound according to claim 1 which is l-butylA[4-(3-methyl-butoxy)-benzenesulfonyl]-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 25. A compound according to claim 1 which is 1-benzyl4[4-(2-ethyl-butoxy)-benzenesulfonyl]-piperidine~carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 26. A compound according to claim 1 which is 4-(4butoxy-benzenesulfonyl)-1-(3-methoxy benzyl)-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 27. A compound according to claim 1 which is 4-(4-methoxy-benzenesulfonyl)-1-(4-thiophen-2-yl-benzyl)-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 28. A compound according to claim 1 which is 4-(4-methoxy-benzenesulfonyl)-1-(4-pyridin-2-yl-benzyl)-piperidine-4-carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 29. A compound according to claim 1 which is 1-(3,Sdichlorobenzyl)4-(4-butoxy-benzenesulfonyl)-piperidine~carboxylic acid hydroxyamide or a pharmaceutical salt thereof.
- 30. A compound according to claim 1 which is [4-(4chloro-benzyloxy)-benzenesulfonyl]-1-methylpiperidine-4-carboxylic acid hydroxamide or a pharmaceutical salt thereof.
- 31. A compound according to claim 1 which is 4-(4-butoxy-benzenesulfonyl)-1-(3-phenoxy-benzyl)-piperidine~carboxylic acid hydroxamide or a pharmaceutical salt thereof.
- 32. A compound according to claim 1 which is [(4chloro-benzyloxy)-benzenesulfonyl]-1-(4-methylbenzyl)-piperidine-4-carboxylic acid hydroxamide or a pharmaceutical salt thereof.
- 33. A compound according to claim 1 which is 4-(4butoxy-benzenesulfonyl)-1-(4 methylbenzyl)-piperidine-4f carboxylic acid hydroxamide or a pharmaceutical salt thereof.
- 34. A compound according to claim 1 which is 4-(4butoxy-benzenesulfonyl)-1-(4cyano benzyl)-piperidine~carboxylic acid hydroxamide or a pharmaceutical salt thereof.
- 35. A compound according to claim 1 which is 4-(4-Butoxy-benzenesulfonyl)-1-pyridin4 ylmethyl-piperidine-4-carboxylic acid hydroxamide or a pharmaceutical salt thereof.
- 36. A compound according to claim 1 or a pharmaceutically acceptable salt thereof which is selected from the group of compounds consisting of:
4-(4-methoxy-benzenesulfonyl)-1-(3-phenyl-propyl)-piperidine-4-carboxylic acid hydroxyamide, 1-tert-butyl-4-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide, 1-butyl-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide, 1-cyclooctyl-4-(4-methoxy-benzenesulfonyl)piperidine-4-carboxylic acid hydroxyamide, 1-ethyl-4-(4-methoxy-benzenesulfonyl)-piperidineAcarboxylic acid hydroxyamide, 1-isopropyl(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide, 1-methyl-4-(4-methoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyamide, 1-benzyl1(4-butoxy-benzenesulfonyl)-piperidine-4-carboxylic acid hydroxyaniide, 1-5 -1-(4fluoro-benzyl)4-(4-methoxy-benzenesulfonyl)-piperidineAcarboxylic acid hydroxyamide, 1-(4-fluoro-benzy])4-(4-butoxy-benzenesulfonyl)-piperidinencarboxylic acid hydroxyamide, 4-(4-methoxy-benzenesulfonyl)-1-(4-methoxy-benzyl)-piperidine-4-carboxylic acid hydroxyamide, 4-(4-methoxy-benzenesulfonyl)-1-[2-(4-methoxyphenyl)-ethyl]-piperidine-4-carboxylic acid hydroxyaride, 4-(4-methoxy-benzenesulfonyl)-1-(2-phenyl-ethyl)-piperidine-4-carboxylic acid hydroxyamide, 4-(4n-butoxy-benzenesulfonyl)-1-(4-methoxy-benzyl)-piperidine-4-carboxylic acid hydroxyamide, 4-(4-methoxy-benzenesulfonyl)-1-(3-phenoxy-propyl)-piperidine-4-carboxylic acid hydroxyamide, 4-(4n-butoxy-benzenesulfonyl)-1-(3-phenoxy-propyl)-piperidine~carboxylic acid hydroxyamide, 4(4-methoxy-benzenesulfonyl)-1-(2-phenoxy-ethyl)-piperidine-4-carboxylic acid hydroxyamide, 4-(4n-butoxy-benzenesulfonyl)-1-(2-phenoxy-ethyl)-piperidine-4-carboxylic acid hydroxyamide, and 4-(4-methoxy-benzenesulfonyl)-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-piperidine-4-carboxylic acid hydroxy amide.
- 37. A method of inhibiting pathological changes mediated by matix metalloproteinases in mammals which comprises administration to a mammal in need thereof a therapeutically effective amount of a matrix metalloproteinase inhibiting compound of the formula
- 38. A method according to claim 37 wherein the condition treated is atherosclerosis, atherosclerotic plaque formation, reduction of coronary thrombosis from atherosclerotic plaque rupture, restenosis, MMP-mediated osteopenias, inflammatory diseases of the central nervous system, skin aging, angiogenesis, tumor metastasis, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, corneal ulceration, abnormal wound healing, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, cirrhosis of the liver, glomerular disease of the kidney, premature rupture of fetal membranes, inflammatory bowel disease, or periodontal disease.
- 39. A method according to claim 37 wherein the condition treated is age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesislneovascularization and corneal graft rejection.
- 40. A method of inhibiting pathological changes mediated by TNF-cA converting enzyme TACE) in mammals which comprises administration to a mammal in need thereof a therapeutically effective amount of a TACE inhibiting compound of the formula
- 41. The method according to claim 40 wherein the condition treated is rheumatoid artritis, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, or HIV infection.
- 42. A pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a matrix metalloproteinase or TACE inhibiting compound according to the formula
Parent Case Info
[0001] This application is a continuation in part of U.S. patent application Ser. No. 09/026,372, filed on Feb. 19, 1998 which claims the benefit of priority of U.S. Provisional Application No. 60/038,899 filed on Feb. 27, 1997.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60038899 |
Feb 1997 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09593918 |
Jun 2000 |
US |
Child |
09899641 |
Jul 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09140504 |
Aug 1998 |
US |
Child |
09593918 |
Jun 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09026372 |
Feb 1998 |
US |
Child |
09140504 |
Aug 1998 |
US |